Copanlisib – Uses, Dosage, Side Effects, Interactions

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 57 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Copanlisib is an intravenously administered phosphatidylinositol-3 kinase inhibitor that is used to treat relapsed and refractory follicular lymphoma. Copanlisib is associated with a high rate of minor serum enzyme elevations during therapy and has been reported to cause clinically apparent acute liver injury that can...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Copanlisib is an intravenously administered phosphatidylinositol-3 kinase inhibitor that is used to treat relapsed and refractory follicular lymphoma. Copanlisib is associated with a high rate of minor serum enzyme elevations during therapy and has been reported to cause clinically apparent acute liver injury that can be severe and even fatal. Copanlisib is a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.
Choose your reading view

Patient View highlights a simple learning journey. Clinical View reveals structure, evidence, and editorial completeness.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Definition

Copanlisib is an intravenously administered phosphatidylinositol-3 kinase inhibitor that is used to treat relapsed and refractory follicular lymphoma. Copanlisib is associated with a high rate of minor serum enzyme elevations during therapy and has been reported to cause clinically apparent acute liver injury that can be severe and even fatal.

Copanlisib is a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in the inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.

Copanlisib Hydrochloride is the dihydrochloride salt form of copanlisib, a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in the inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.

Copanlisib is an imidazoquinazoline that is 2,3-dihydroimidazo[1,2-c]quinazoline substituted by (2-aminopyrimidine-5-carbonyl)amino, methoxy, and 3-(morpholine-4-yl)propoxy groups at positions 5, 7 and 8, respectively. It is an intravenous pan-class I PI3K inhibitor used for the treatment of relapsed follicular lymphoma in patients who have received at least 2 prior systemic therapies. It has a role as an EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor, an antineoplastic agent, and an apoptosis inducer. It is a member of morpholines, an aromatic ether, a diether, a tertiary amine compound, a secondary carboxamide, a pyrimidinecarboxamide, an aminopyrimidine, and an imidazoquinazoline.

Mechanism of Action

Follicular lymphoma is a B-cell lymphoma that is one of the most common types of non-Hodgkin lymphoma (NHL). It involves unregulated growth and proliferation of lymphocytes that eventually may travel to other organs including the lymph nodes, spleen, and bone marrow, to form tumors. The phosphatidylinositol 3-kinase (PI3K)-the mediated pathway is involved in promoting cell survival proliferation and differentiation however aberrant activation of this pathway may lead to tumorigenesis. Copanlisib mediates an inhibitory action on p110α and p110δ isoforms of phosphatidylinositol-3-kinase (PI3K) expressed in malignant B cells. It induces tumor cell death via apoptosis and inhibits the proliferation of primary malignant B cell lines. Copanlisib inhibits several key cell-signaling pathways, including B-cell receptor (BCR) signaling, CXCR12-mediated chemotaxis of malignant B cells, and NFκB signaling in lymphoma cell lines.

Copanlisib has demonstrated potent anti-tumor and pro-apoptotic activity in various tumor cell lines and xenograft models. In clinical trials, 59 percent of patients receiving copanlisib achieved complete or partial shrinkage of their tumors after a median of 12.2 months. Higher systemic levels of copanlisib are associated with elevated plasma glucose levels.

Indications

  • Indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
  • Treatment of all conditions included in the category of malignant neoplasms (except hematopoietic and lymphoid tissue), Treatment of mature B-cell neoplasms
  • Relapsed Follicular Lymphoma

Contraindications

The following conditions are contraindicated with this drug. Check with your physician if you have any of the following:

  • a bad infection
  • decreased blood platelets
  • low levels of a type of white blood cell called neutrophils
  • high blood pressure
  • x-ray results showing lung tissue changes
  • high blood sugar
  • pregnancy
  • a patient who is producing milk and breastfeeding

Dosage

Strengths: 60 mg

Follicular Lymphoma

  • 60 mg via 1-hour IV infusion on Days 1, 8, and 15 of a 28-day treatment cycle on an intermittent schedule (3 weeks on and 1 week off).
  • Duration of Therapy: Until disease progression or unacceptable toxicity

Dose Adjustments

CONCOMITANT USE WITH STRONG CYP450 3A INDUCERS: Not recommended.

CONCOMITANT USE WITH STRONG CYP450 3A INHIBITORS: Reduce dose to 45 mg.

TOXICITY MANAGEMENT:
INFECTIONS:

  • Grade 3 or Higher: Withhold this drug until resolution.
  • Suspected Pneumocystis Jiroveci Pneumonia (PJP) Infection of Any Grade: Withhold this drug; if PJP confirmed, treat infection until resolution then resume this drug at previous dose with concomitant PJP prophylaxis.

HYPERGLYCEMIA:

  • Pre-Dose Fasting Blood Glucose 160 mg/dL or More OR Random/Non-Fasting Blood Glucose of 200 mg/dL or More: Withhold this drug until fasting glucose is 160 mg/dL or less or a random/non-fasting blood glucose of 200 mg/dL or less.
  • Pre-Dose OR Post-Dose Blood Glucose 500 mg/dL or More: Withhold this drug until fasting glucose is 160 mg/dL or less or a random/non-fasting blood glucose of 200 mg/dL or less; then reduce dose:
  • First Occurrence: Reduce dose from 60 mg to 45 mg and maintain.
  • Second Occurrence: Reduce dose from 45 mg to 30 mg and maintain.
  • If Hyperglycemia Persistent at 30 mg: Discontinue this drug.

HYPERTENSION:

  • Pre-Dose Blood Pressure (BP) 150/90 or Greater: Withhold this drug until BP is less than 150/90 based on 2 consecutive BP measurements at least 15 minutes apart.
  • Post-Dose BP 150/90 or Greater (Non-Life-Threatening):
  • Anti-Hypertensive Treatment Not Required: Continue this drug at previous dose.
  • Anti-Hypertensive Treatment Is Required: Consider dose reduction from 60 mg to 45 mg OR from 45 mg to 30 mg.
  • If BP Remains Uncontrolled (Greater than 150/90) Despite Anti-Hypertensive Treatment OR Post-Dose Elevated BP with Life-Threatening Consequences: Discontinue this drug.

NON-INFECTIOUS PNEUMONITIS (NIP):

  • Grade 2: Withhold this drug and treat NIP; resume this drug at 45 mg if NIP recovers to Grade 0 or 1.
  • Grade 2 Recurrence OR Grade 3 or Higher: Discontinue this drug.

bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।" data-rx-term="neutrophil" data-rx-definition="Neutrophil is a white blood cell important for fighting bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।">neutrophil count, which may increase infection risk. সহজ বাংলা: নিউট্রোফিল কম থাকা, সংক্রমণের ঝুঁকি বাড়তে পারে।" data-rx-term="neutropenia" data-rx-definition="Neutropenia means low neutrophil count, which may increase infection risk. সহজ বাংলা: নিউট্রোফিল কম থাকা, সংক্রমণের ঝুঁকি বাড়তে পারে।">NEUTROPENIA:

  • Absolute bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।" data-rx-term="neutrophil" data-rx-definition="Neutrophil is a white blood cell important for fighting bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।">Neutrophil Count (ANC) 0.5 to 1 x 10(3) cells/mm3: Maintain dose, and monitor ANC at least weekly.
  • ANC Less Than 0.5 x 10(3) cells/mm3: Withhold this drug. Monitor ANC at least weekly until ANC 0.5 x 10(3) cells/mm3 or greater, then resume at previous dose.
  • Recurrence of ANC 0.5 x 10(3) cells/mm3 or Less: Reduce dose to 45 mg.

SEVERE CUTANEOUS REACTIONS:

  • Grade 3: Withhold this drug until toxicity is resolved, and reduce dose from 60 mg to 45 mg OR from 45 mg to 30 mg.
  • Life-Threatening: Discontinue this drug.

platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।" data-rx-term="thrombocytopenia" data-rx-definition="Thrombocytopenia means low platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।">THROMBOCYTOPENIA:

  • Less Than 25 x 10(9)/L: Withhold this drug; resume when platelet levels return to 75 x 10(9)/L or greater.
  • If Recovery Occurs Within 21 Days: Reduce dose from 60 mg to 45 mg OR from 45 mg to 30 mg.
  • If Recovery Does Not Occur Within 21 Days: Discontinue this drug.

OTHER SEVERE AND NON-LIFE-THREATENING TOXICITIES:

  • Grade 3: Withhold this drug until toxicity is resolved, and reduce dose from 60 mg to 45 mg OR from 45 mg to 30 mg.
  • Ensure a minimum of 7 days between any 2 consecutive infusions.

Side Effects

The Most Common

  • diarrhea
  • nausea
  • vomiting
  • mouth sores, ulcers, or pain
  • burning, prickling, tingling, or numb feeling on the skin
  • pain upon touch
  • swelling of nose, throat, or mouth
  • lack of strength or energy
  • unusual bleeding or bruising
  • new or worsening cough, shortness of breath, or difficulty breathing
  • rash; or red, itching, peeling or swelling skin
  • fever, sore throat, chills, or other signs of infection
  • feeling very hungry or thirsty, pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।" data-rx-term="headache" data-rx-definition="Headache means pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।">headache, or frequent urination

More Common

  • a new or worsening cough, chest pain, or trouble breathing;
  • severe skin redness, itching, or swelling;
  • easy bruising, unusual bleeding;
  • signs of infection–fever, chills, cold or flu symptoms, mouth sores, skin sores;
  • high blood sugar–increased thirst, increased urination, hunger, headache, blurred vision, fruity breath odor; or
  • increased blood pressure–severe headache, pounding in your neck or ears, dizziness, or feeling like you might pass out.
  • infections, bruising, or bleeding;
  • feeling weak or tired;
  • nausea, diarrhea; or
  • trouble breathing.

Rare

  • Black, tarry stools
  • bleeding gums
  • blood in the urine or stools
  • blurred vision
  • chest pain
  • chills
  • cough
  • cracks in the skin
  • dizziness
  • dry mouth
  • fatigue
  • flushed, dry skin
  • fruit-like breath odor
  • headache
  • increased hunger
  • increased thirst
  • increased urination
  • loss of heat from the body
  • lower back or side pain
  • nausea
  • nervousness
  • painful or difficult urination
  • pale skin
  • pinpoint red spots on the skin
  • pounding in the ears
  • red, swollen skin
  • scaly skin
  • slow or fast heartbeat
  • sneezing
  • sore throat
  • sores, ulcers, or white spots on the lips or in the mouth
  • stomach pain
  • sweating
  • swollen glands
  • tightness in the chest
  • troubled breathing
  • unexplained weight loss
  • unusual bleeding or bruising
  • unusual tiredness or weakness

Drug Interaction

Drug-Food Interactions

  • Avoid grapefruit products. Grapefruit inhibits CYP3A metabolism, which may increase the serum concentration of copanlisib.
  • Avoid St. John’s Wort. This herb induces the CYP3A metabolism of copanlisib and may reduce its serum concentration.

Pregnancy and Lactation

US FDA pregnancy category Not Assigned

Pregnancy

The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help healthcare providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out. Safety has not been established during pregnancy; based on animal studies and its mechanism of action, this drug can cause fetal harm and is expected to cause adverse fertility effects.

Lactation

No information is available on the clinical use of copanlisib during breastfeeding. Because copanlisib’s half-life is about 39 hours, it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during copanlisib therapy and for 1 month after the last dose.

What special precautions should I follow?

Before receiving copanlisib injection,

  • tell your doctor and pharmacist if you are allergic to copanlisib, any other medications, or any of the ingredients in copanlisib injection. Ask your pharmacist for a list of the ingredients.
  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements and herbal products you are taking or plan to take. Be sure to mention any of the following: boceprevir (Victrelis); carbamazepine (Carbatrol, Equetro, Tegretol, others), clarithromycin (Biaxin, in Prevpac), cobicistat (Tybost, in Evotaz, Genvoya, Prezcobix, Stribild), conivaptan (Vaprisol), diltiazem (Cardizem, Cartia XT, Diltzac, others), efavirenz (Sustiva), enzalutamide (Xtandi), idelalisib (Zydelig), indinavir (Crixivan) with ritonavir; itraconazole (Sporonox, Onmel), and ketoconazole, lopinavir with ritonavir (in Kaletra); mitotane (Lysodren), nefazodone, nelfinavir (Viracept), nevirapine (Viramune), paritaprevir, ritonavir, ombitasvir, and/or dasabuvir (Viekira Pak); phenobarbital, phenytoin (Dilantin, Phenytek), posaconazole (Noxafil), rifabutin (Mycobutin), rifampin (Rifadine, in Rifamate, Rifater), ritonavir (Norvir, in Kaletra, Technivie, Viekira Pak), saquinavir (Invirase), and tipranavir (Aptivus) with ritonavir; and voriconazole (Vfend). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with copanlisib injection, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
  • tell your doctor what herbal products you are taking, especially St. John’s wort.
  • tell your doctor if you have an infection or if you have or have ever had high blood sugar, diabetes, lung or breathing problems, high blood pressure, or liver disease.
  • tell your doctor if you are pregnant, plan to become pregnant, or plan to father a child. You should not become pregnant while you are receiving copanlisib injection. You will need to have a negative pregnancy test before you begin receiving this medication. Use effective birth control during your treatment with copanlisib injection and for 1 month after your final dose. If you are a male and your partner can become pregnant, you should use effective birth control during your treatment and for 1 month after your final dose. If you or your partner become pregnant while receiving copanlisib, call your doctor.
  • tell your doctor if you are breastfeeding. You should not breastfeed while you are receiving copanlisib injection, and for 1 month after your final dose.
  • you should know that this medication may decrease fertility in men and women. Talk to your doctor about the risks of receiving copanlisib injection.

Warning

Infection

Serious infection has occurred in patients receiving copanlisib therapy; some cases were fatal. Monitor patients for signs and symptoms of infection; hold therapy for grade 3 or higher infection. Serious pneumocystis jiroveci pneumonia (PJP) has occurred with copanlisib use; consider PJP prophylaxis in at-risk patients before initiating therapy. Hold therapy if PJP is suspected. If PJP diagnosis is confirmed, treat the infection until resolution and then resume copanlisib at the previous dose and give PJP prophylaxis for the duration of therapy.

Diabetes mellitus, hyperglycemia

Severe hyperglycemia, elevated HbA1c, and infusion-related hyperglycemia have occurred with copanlisib therapy; additionally, serious hyperglycemic events have been reported. Monitor blood glucose levels before and after the copanlisib infusion. Therapy interruption, dose reduction, or therapy discontinuation may be necessary in patients who develop hyperglycemia. Blood glucose levels typically peak at 5 to 8 hours post infusion and then decline to baseline levels in most patients. Use copanlisib with caution in patients with diabetes mellitus. Initiate copanlisib therapy only after these patients have achieved optimal blood glucose control; monitor blood glucose levels in these patients closely.

Hypertension

Severe hypertension and infusion-related hypertension have occurred with copanlisib therapy; use copanlisib with caution in patients with pre-existing hypertension. Monitor blood pressure before and after the copanlisib infusion; optimal blood pressure control should be achieved prior to each dose. Therapy interruption, dose reduction, or therapy discontinuation may be necessary in patients who develop hypertension. A mean increase in systolic (+16.8 mmHg) and diastolic (+7.8 mmHg) blood pressure was observed at 2 hours post infusion on day 1 of cycle 1 of copanlisib therapy; blood pressure typically remained elevated for 6 to 8 hours after the start of the infusion.

Pneumonitis, pulmonary disease

Non-infectious pneumonitis has occurred with copanlisib therapy; use copanlisib with caution in patients with pre-existing pulmonary disease. Hold therapy and evaluate patients who experience signs or symptoms of pneumonitis (e.g., cough, dyspnea, hypoxia, and interstitial infiltrates on X-ray exam). Therapy interruption, dose reduction, or therapy discontinuation may be necessary in patients who develop pneumonitis. The use of systemic corticosteroid may be beneficial in these patients.

Neutropenia, thrombocytopenia

Severe hematologic toxicity including neutropenia and thrombocytopenia has occurred with copanlisib therapy. Monitor complete blood counts at least weekly during treatment. Therapy interruption, dose reduction, or therapy discontinuation may be necessary in patients who develop severe neutropenia or thrombocytopenia.

Serious rash

Severe cutaneous reactions (e.g., serious rash) have occurred with copanlisib therapy. Therapy interruption, dose reduction, or therapy discontinuation may be necessary in patients who develop severe skin reactions.

Hepatic disease

Reduce the dose of copanlisib in patients with moderate hepatic disease/impairment (Child-Pugh class B). Copanlisib has not been studied in patients with severe hepatic impairment (Child-Pugh class C). Evaluate liver function tests at baseline and as clinically appropriate during therapy.

Geriatric

Geriatric patients with follicular lymphoma or other hematologic malignancies had a higher incidence of serious adverse reactions compared with patients aged less than 65 years (30% vs. 23%) after treatment with single-agent copanlisib in a pooled analysis from clinical trials (n = 168). However, an initial dose adjustment is not necessary in patients 65 years or older.

Pregnancy

Copanlisib can cause fetal harm when administered during pregnancy, based on its mechanism of action and data from animal studies. Females of reproductive potential should avoid becoming pregnant while receiving copanlisib. Advise patients to notify their healthcare provider immediately if they become pregnant or if pregnancy is suspected during treatment. Embryo-fetal toxicities including embryo-fetal death and fetal abnormalities (e.g., domed head, malformed eyeballs or eyeholes, hydrocephalus internus, ventricular septal defects, major vessel malformations, dysplastic forelimb bones, malformed ribs and vertebrae, and pelvis shift) were observed when copanlisib was administered to pregnant rats during organogenesis at doses corresponding to approximately 12% the recommended dose in humans.

Contraception requirements, infertility, male-mediated teratogenicity, pregnancy testing, reproductive risk

Counsel patients about the reproductive risk and contraception requirements during copanlisib treatment. Pregnancy testing prior to starting therapy is recommended for females of reproductive potential. These patients should avoid pregnancy and use highly effective contraception during therapy and for 1 month after the last copanlisib dose. Due to the risk of male-mediated teratogenicity, men with female partners of reproductive potential should avoid fathering a child and use effective contraception during and for 1 month after copanlisib therapy. Adverse effects on male and female reproduction (e.g., infertility) are expected based on findings from animal studies.

Breast-feeding

It is not known whether copanlisib or its metabolites are secreted in human milk or if it has effects on the breast-fed infant or on milk production. Because of the potential for serious adverse reactions in nursing infants, women should discontinue breast-feeding during copanlisib therapy and for 1 month after the last dose.

References

  1. https://pubchem.ncbi.nlm.nih.gov/compound/Copanlisib
  2. https://pubchem.ncbi.nlm.nih.gov/compound/Copanlisib-hydrochloride
  3. https://www.pdr.net/drug-summary/ALIQOPA-copanlisib-24140
  4. https://www.drugs.com/pregnancy/copanlisib.html
  5. https://www.webmd.com/drugs/2/drug-174130/copanlisib-intravenous/details/list-contraindications
  6. https://go.drugbank.com/drugs/DB12483
  7. https://medlineplus.gov/druginfo/meds/a617044.html
  8. DrugBank
    LICENSE
    Creative Common’s Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode)
    https://www.drugbank.ca/legal/terms_of_use
    Copanlisib
    https://www.drugbank.ca/drugs/DB12483
  9. FDA Pharm Classes
    LICENSE
    Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    COPANLISIB
    https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm
    FDA Pharmacological Classification
    https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm
  10. LiverTox
    LICENSE
    https://www.nlm.nih.gov/copyright.html
    Copanlisib
    https://www.ncbi.nlm.nih.gov/books/n/livertox/Copanlisib/
  11. NCI Thesaurus (NCIt)
    LICENSE
    Unless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.
    https://www.cancer.gov/policies/copyright-reuse
    https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C96796
    NCI Thesaurus Tree
    https://ncit.nci.nih.gov
  12. ChEMBL
    LICENSE
    Access to the web interface of ChEMBL is made under the EBI’s Terms of Use (http://www.ebi.ac.uk/Information/termsofuse.html). The ChEMBL data is made available on a Creative Commons Attribution-Share Alike 3.0 Unported License (http://creativecommons.org/licenses/by-sa/3.0/).
    http://www.ebi.ac.uk/Information/termsofuse.html
    https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3218576/
    ChEMBL Protein Target Tree
    https://www.ebi.ac.uk/chembl/g/#browse/targets
  13. Comparative Toxicogenomics Database (CTD)
    LICENSE
    It is to be used only for research and educational purposes. Any reproduction or use for commercial purpose is prohibited without the prior express written permission of NC State University.
    http://ctdbase.org/about/legal.jsp
    https://ctdbase.org/detail.go?type=chem&acc=C000589253
  14. Drug Gene Interaction database (DGIdb)
    LICENSE
    The data used in DGIdb is all open access and where possible made available as raw data dumps in the downloads section.
    http://www.dgidb.org/downloads
    https://www.dgidb.org/drugs/COPANLISIB
  15. ChemIDplus
    LICENSE
    https://www.nlm.nih.gov/copyright.html
    Copanlisib [USAN:INN]
    https://chem.nlm.nih.gov/chemidplus/sid/1032568630
    ChemIDplus Chemical Information Classification
    https://chem.nlm.nih.gov/chemidplus/
  16. EPA DSSTox
    LICENSE
    https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources
    Copanlisib
    https://comptox.epa.gov/dashboard/DTXSID00145728
    CompTox Chemicals Dashboard Chemical Lists
    https://comptox.epa.gov/dashboard/chemical-lists/
  17. European Chemicals Agency (ECHA)
    LICENSE
    Use of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: “Source: European Chemicals Agency, http://echa.europa.eu/”. Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.
    https://echa.europa.eu/web/guest/legal-notice
    2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyrimidine-5-carboxamide
    https://echa.europa.eu/information-on-chemicals
  18. ClinicalTrials.gov
    LICENSE
    The ClinicalTrials.gov data carry an international copyright outside the United States and its Territories or Possessions. Some ClinicalTrials.gov data may be subject to the copyright of third parties; you should consult these entities for any additional terms of use.
    https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
    https://clinicaltrials.gov/
  19. European Medicines Agency (EMA)
    LICENSE
    Information on the European Medicines Agency’s (EMA) website is subject to a disclaimer and copyright and limited reproduction notices.
    https://www.ema.europa.eu/en/about-us/legal-notice
    Copanlisib (P/0402/2020)
    https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001757-pip02-15-m02
  20. Drugs and Lactation Database (LactMed)
    LICENSE
    https://www.nlm.nih.gov/copyright.html
    Copanlisib
    https://www.ncbi.nlm.nih.gov/books/NBK500940/
  21. EU Clinical Trials Register
    https://www.clinicaltrialsregister.eu/
  22. FDA Orange Book
    LICENSE
    Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
  23. FDA Global Substance Registration System (GSRS)
    LICENSE
    Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    WI6V529FZ9
    https://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSystem-UniqueIngredientIdentifierUNII/
  24. National Drug Code (NDC) Directory
    LICENSE
    Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    COPANLISIB
    https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
  25. Human Metabolome Database (HMDB)
    LICENSE
    HMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications.
    http://www.hmdb.ca/citing
    Copanlisib
    http://www.hmdb.ca/metabolites/HMDB0250446
  26. NCI Cancer Drugs
    LICENSE
    https://www.cancer.gov/policies/copyright-reuse
    Aliqopa (Copanlisib Hydrochloride)
    https://www.cancer.gov/about-cancer/treatment/drugs/copanlisibhydrochloride
  27. NLM RxNorm Terminology
    LICENSE
    The RxNorm Terminology is created by the National Library of Medicine (NLM) and is in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from NLM. Credit to the U.S. National Library of Medicine as the source is appreciated but not required. The full RxNorm dataset requires a free license.
    https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html
    https://rxnav.nlm.nih.gov/id/rxnorm/1945077
  28. Protein Data Bank in Europe (PDBe)
    http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6E2
  29. Springer Nature
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=35052508-983538942
  30. Thieme Chemistry
    LICENSE
    The Thieme Chemistry contribution within PubChem is provided under a CC-BY-NC-ND 4.0 license, unless otherwise stated.
    https://creativecommons.org/licenses/by-nc-nd/4.0/
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=35052508-983539296
  31. WHO Anatomical Therapeutic Chemical (ATC) Classification
    LICENSE
    Use of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed.
    https://www.whocc.no/copyright_disclaimer/
    https://www.whocc.no/atc/
    ATC Code
    https://www.whocc.no/atc_ddd_index/
  32. Wikidata
    LICENSE
    CCZero
    https://creativecommons.org/publicdomain/zero/1.0/
    Copanlisib
    https://www.wikidata.org/wiki/Q19903876
  33. PubChem
    https://pubchem.ncbi.nlm.nih.gov
  34. Medical Subject Headings (MeSH)
    LICENSE
    Works produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S.
    https://www.nlm.nih.gov/copyright.html
    copanlisib
    https://www.ncbi.nlm.nih.gov/mesh/2001158
    MeSH Tree
    http://www.nlm.nih.gov/mesh/meshhome.html
  35. KEGG
    LICENSE
    Academic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial license
    https://www.kegg.jp/kegg/legal.html
    USP drug classification
    http://www.genome.jp/kegg-bin/get_htext?br08302.keg
    Anatomical Therapeutic Chemical (ATC) classification
    http://www.genome.jp/kegg-bin/get_htext?br08303.keg
    Target-based classification of drugs
    http://www.genome.jp/kegg-bin/get_htext?br08310.keg
    Drug Groups
    http://www.genome.jp/kegg-bin/get_htext?br08330.keg
  36. IUPHAR/BPS Guide to PHARMACOLOGY
    LICENSE
    The Guide to PHARMACOLOGY database is licensed under the Open Data Commons Open Database License (ODbL) https://opendatacommons.org/licenses/odbl/. Its contents are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License (http://creativecommons.org/licenses/by-sa/4.0/)
    https://www.guidetopharmacology.org/about.jsp#license
    Guide to Pharmacology Target Classification
    https://www.guidetopharmacology.org/targets.jsp
  37. NORMAN Suspect List Exchange
    LICENSE
    Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0
    https://creativecommons.org/licenses/by/4.0/
    NORMAN Suspect List Exchange Classification
    https://www.norman-network.com/nds/SLE/
  38. PATENTSCOPE (WIPO)
    SID 471048692
    https://pubchem.ncbi.nlm.nih.gov/substance/471048692

RX Clinical Pathway Engine

Continue through a complete learning pathway

Move from understanding the topic to symptoms, tests, treatment, medicines, monitoring, and prevention.

Search the complete library
  1. Understand the condition Begin with the essential facts and a clear explanation of the topic.
  2. Recognize symptoms Learn common symptoms, signs, and patterns of presentation.
  3. Know when to seek help Review urgent warning signs and when professional assessment may be needed.
  4. Understand causes and risks Explore causes, risk factors, mechanisms, and contributing conditions.
  5. Explore tests and diagnosis Learn how clinicians assess the condition and which investigations may be discussed.
  6. Learn treatment approaches Review general treatment categories and management principles.
  7. Understand medicines safely Continue to medicine education, uses, precautions, and monitoring.
  8. Plan monitoring and follow-up Understand monitoring, complications, rehabilitation, and follow-up learning.
  9. Review prevention and self-care Explore prevention, healthy routines, and questions to discuss with a clinician.

Conditions & Diseases

Background, symptoms, causes, diagnosis, and care.

Explore this library

Tests & Investigations

Laboratory, imaging, screening, and diagnostic education.

Explore this library

Medicines

Uses, safety, monitoring, and related medicine knowledge.

Explore this library

Cancer Knowledge

Cancer types, screening, oncology, and treatment education.

Explore this library
Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Copanlisib – Uses, Dosage, Side Effects, Interactions

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Is this article a replacement for a doctor?

No. It is educational content only. Patients should consult a qualified clinician for diagnosis and treatment.

When should I seek urgent care?

Seek urgent care for severe symptoms, rapidly worsening condition, breathing difficulty, severe pain, neurological changes, or any emergency warning sign.

Continue exploring

Explore this topic across the RX Medical Library

Open a focused A–Z pathway or continue with closely related indexed articles. These links are educational and do not replace personal medical care.

Search this topic
Diseases A–Z Drugs A–Z Lab Tests A–Z Cancer A–Z
Diseases A–Z

Foodborne Illness (also foodborne disease and colloquially referred to as food poisoning)[rx] is any illness resulting from the spoilage of contaminated food, pathogenic bacteria, viruses, or parasites that…

More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain? Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)